Eli Lilly is making decisive moves in the competitive weight loss drug market, including the acquisition of Ajax Therapeutics for up to $2.3 billion. This follows its successful navigation of regulatory hurdles and a promising FDA approval for its obesity drug, orforglipron. Despite a recent dip in share price due to initial prescription sluggishness, analysts remain optimistic, adjusting price targets upward and projecting strong earnings for FY 2026. Jim Cramer underscores Lilly's commitment to leading the weight loss race against rival Novo Nordisk.
“I’m a Eli Lilly guy, okay? I’m going to stick with it.”
“Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders.”
“Coca-Cola just rewarded its shareholders again. This Warren Buffett favorite has grown its dividend for 62 straight years.”
“Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024.”
“Viking Therapeutics is a clinical-stage biopharma company focused on metabolic disorders, including obesity and non-alcoholic steatohepatitis (NASH).”
“As of the latest data, VK5211 is in Phase 2 trials.”
“Lilly, on the other hand, has a decades-long history of navigating regulatory landscapes.”
“Lilly, with a $200 billion market cap, trades at a forward P/E of 21x.”
“Its dividend yield of 2.3% adds downside protection.”
“And now, Amazon is using these strengths to launch a new service that addresses the needs of patients who want to lose weight.”
“Today, Eli Lilly and Novo Nordisk dominate the GLP-1 drug market, selling Zebound and Wegovy, respectively.”
“Amazon's Partnership With Anthropic Keeps Deepening.”
